Recent Updates
Recently added Catalysts
EW Positive Sentiment

Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients

Key Takeaway: Edwards Lifesciences has received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve tailored for pediatric patients with congenital heart disease. This innovative valve addresses the ongoing need for pulmonary valve replacement in children, marking a significant advancement in pediatric cardiac care.

Market Sentiment Analysis

POSITIVE FACTORS

  • First FDA-approved surgical pulmonary valve for pediatric patients.
  • Specifically designed for pediatric anatomy.
  • Addresses a critical need for congenital heart disease patients.

Full Press Release Details

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy,

Frequently Asked Questions

What is the AUTUS Valve?

The AUTUS Valve is a surgical pulmonary valve approved for pediatric patients.

Who is the AUTUS Valve designed for?

It is specifically designed for pediatric patients with congenital heart disease.

What does FDA approval mean for the AUTUS Valve?

FDA approval signifies that the valve meets safety and efficacy standards for use.

Why is the AUTUS Valve significant?

It is the first FDA-approved surgical pulmonary valve tailored for pediatric anatomy.

Last updated: Oct 1, 2026